Clinical trials: Efavirenz
Efavirenz, Metabolism and Pharmacokinetics Changes
Determine the Effects of Gene Differences and Voriconazole on Enzyme CYP2B6 Activity in the Liver in Healthy Volunteers
The purpose of this study is to see if administration of medicines and genetic differences affects the activity of a liver enzyme called CYP2B6 in healthy volunteers.
- Trial name
- NCT01104376
- Testing
- Efavirenz, voriconazole
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Indiana University
HIV
Effects of CYP2B6 Genetic Polymorphisms on Efavirenz Pharmacokinetics
1. To see how the liver breaks down efavirenz by an enzyme called CYP2B6. It is suggested that when Efavirenz is taken repeatedly it may increase the amount of CYP2B6 in your liver and thus speed up your liver's ability to get…
- Trial name
- NCT00668395
- Testing
- Efavirenz
- Where
- 2 sites in United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Indiana University
Healthy Volunteer
A Study of Potential Drug-Drug Interaction Between Efavirenz and Danoprevir With Low Dose Ritonavir in Healthy Volunteers
This phase 1, randomized, open-label, multiple-dose, 2-sequence, 2-period crossover study will evaluate potential drug-drug interaction between efavirenz and danoprevir with low-dose ritonavir in healthy volunteers. In Period 1.
- Trial name
- NCT01588002
- Testing
- danoprevir, efavirenz, ritonavir
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Infections, Human Immunodeficiency Virus and Herpesviridae
GSK1349572 Drug Interaction Study With Efavirenz
GSK1349572 is an integrase inhibitor that is currently in Phase 2 clinical trials for the treatment of HIV infection. As GSK1349572 development progresses, it may be dosed with non-nucleoside HIV reverse transcriptase inhibitors…
- Trial name
- NCT01098526
- Testing
- GSK1349572, Efavirenz
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Healthy
CYP2B6 Genetics and Drug Interactions in Healthy Volunteers
The CYP2B6 enzyme metabolizes a growing number of clinically important drugs such as the anti-HIV drug efavirenz, but its activity in the liver is highly variable, which may lead to failure of therapy or toxicity and…
- Trial name
- NCT02401256
- Testing
- Efavirenz, Bupropion, Rosuvastatin
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Indiana University
Healthy
Bioequivalence Study of Two Formulatiosns With the Asscociaton of Efavirenz, Emtricitabine and Tenofovir
Bioequivalence study of two formulations containing a fixed dose combination of 600 mg Efavirenz, 200 mg Emtricitabine and 300 mg Tenofovir Disproxyl Fumarate in coated tablets under a single-dose, two-way crossover design.
- Trial name
- NCT03309566
- Testing
- Efavirenz, tenofovir disoproxil fumarate and emtricitabine
- Where
- Argentina
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Laboratorio Elea Phoenix S.A.
Acquired Immune Deficiency Syndrome, Human Immunodeficiency Virus
Dose Optimisation of Stavudine for the Treatment of HIV Infection
The purpose of this study is to demonstrate whether low dose stavudine (d4T) is non-inferior (in terms of both viral suppression and toxicity) to tenofovir (TDF) after 2 years of HIV treatment.
- Trial name
- D4T (NCT02670772)
- Testing
- Stavudine, Tenofovir Disoproxil Fumarate
- Where
- 3 sites in India, South Africa and 1 more
- Volunteers
- 1,077 people, healthy volunteers welcome
- Sponsor
- Willem Daniel Francois Venter